Diamedica Therapeutics Inc. · NASDAQ:DMAC
Diamedica Therapeutics — Investor Presentation (June 2026)
39 slides from Diamedica Therapeutics's investor presentation, June 2026
Slide 1: Corporate Presentation
Corporate Presentation June 2026 Transforming Care for Preeclampsia and Stroke
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management’s current expe
Slide 3: DM199: Lead Program Positioned to Drive Near- and Mid-Term Value
DM199: Lead Program Positioned to Drive Near- and Mid-Term Value Recombinant human KLK1 protein for vascular and ischemic diseases Preeclampsia (PE) and Fetal Well-capitalized with multiple Acute Ischemic Stroke (AIS) Growth Restriction (FGR) mid-term value catalysts Ongoing Phase 2 PE Basket Trial
Slide 4: DiaMedica Pipeline
DiaMedica Pipeline COMPOUND INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 UPCOMING MILESTONES** Early-Onset SC dosing until delivery FPI 4Q 2026 Extension Dose-escalation IV/SC Preeclampsia Late-Onset* Cohort Extension Q2 2026 (Delivery Within 72h) IV continuous dosing until delivery FPI Q3 2026 DM
Slide 5: DM199 MOA
DM199 MOA SY’Z DiaMedica AWS THERAPEUTICS
Slide 6: DM199 (rhKLK1 – rinvecalinase alfa) Novel Mechanism of Action
DM199 (rhKLK1 – rinvecalinase alfa) Novel Mechanism of Action DM199 produces all three major endothelial derived vasodilating factors DM199 (rhKLK1) Nitric Oxide - cGMP Kininogen Bradykinin BK2R Prostacyclin - cAMP EDHFs 〉 DM199 (rhKLK1) activates the kallikrein-kinin pathway to increase bradykinin
Slide 7: DM199 Enhances All 3 Major Endothelial-Derived Vasodilating Pathways
DM199 Enhances All 3 Major Endothelial-Derived Vasodilating Pathways1 All three pathways contribute to vasodilation, with EDHF becoming dominant in small resistance vessels (arterioles) Conduit Arteries Terminal Branches Arterioles 〉 Conduit and terminal arteries: – Vasodilation driven primarily by
Slide 8: KLK1 Levels Lower in Preeclampsia Pregnancies
KLK1 Levels Lower in Preeclampsia Pregnancies Significant relationship between KLK1 levels, preeclampsia and preeclampsia with severe features 4 Control Preeclampsia 3 Preeclampsia with severe features KLK1 (ng/mL) serum Levels 2.093 2 1.311 0.763 1 n=45 n=45 n=31 n=3 n=20 0 n=2 1 Control Preeclamps
Slide 9: Preeclampsia & Fetal Growth Restriction
Preeclampsia & Fetal Growth Restriction
Slide 10: Early-Onset Preeclampsia & FGR: Severe Conditions with $5B+ U.S. Opportunity
Early-Onset Preeclampsia & FGR: Severe Conditions with $5B+ U.S. Opportunity Refractory hypertension drives ~50% of deliveries1 Disease Overview Annual Incidence 〉Preeclampsia (PE): A life-threatening hypertensive disorder accompanied by multi- PE Globally2 ~10,000,000 system organ damage occurring
Slide 11: Preeclampsia - Early Delivery Has Poorer Outcomes and Higher Costs
Preeclampsia - Early Delivery Has Poorer Outcomes and Higher Costs Extending pregnancy can reduce neonate morbidity, mortality and associated costs Preterm Neonatal Morbidity* and Mortality by Gestational Age at Birth 90% Death 80% Major Morbidity Minor Morbidity 70% Percentage of neonates (%) 60% 5
Slide 12: Stage 1 of Preeclampsia: Placental Disease
Stage 1 of Preeclampsia: Placental Disease Inadequate spiral artery development in the first trimester leads to reduced blood flow and placental hypoxia Normal Pregnancy Preeclampsia Healthy Blood Flow Low Blood Flow Widened Narrow Spiral Spiral Arteries Arteries (5- to 10- fold)1 Placental Placenta
Slide 13: Stage 2 of Preeclampsia: Endothelial Dysfunction & Maternal Disease
Stage 2 of Preeclampsia: Endothelial Dysfunction & Maternal Disease Reduced placental blood flow and endothelial dysfunction contribute to systemic maternal and fetal complications KLK1 Placental Disease / Endothelial Dysfunction Systemic Disease Placental Hypoxia Maternal Vessel Disease Nitric Oxid
Slide 14: DM199: The Ideal Drug Profile to Treat Preeclampsia
DM199: The Ideal Drug Profile to Treat Preeclampsia Potential disease modifying mechanism of action rhKLK1 Increase Placental Repair Endothelium & Reduce Blood Pressure Perfusion Nitric Oxide Oxidative stress DM199 (rhKLK1) Prostacyclin O2 - ROS Disease Modifying EDHFs Potential to: IL-6 sENG TNF⍺ V
Slide 15: Preeclampsia: Limited Treatment Options - Major Unmet Medical Need
Preeclampsia: Limited Treatments Options - Major Unmet Medical Need 〉No disease modifying agents for preeclampsia 〉First-line antihypertensives, ACE inhibitors and ARBs, are CONTRAINDICATED in pregnancy Medication Drugs Comments Alpha/Beta blocker (Labetalol) Reduce blood pressure and material strok
Slide 16: DM199 Preeclampsia Interim Phase 2 (Part 1a) Results
DM199 Preeclampsia Interim Phase 2 (Part 1a) Results
Slide 17: DM199 Preeclampsia Phase 2 IST Trial: Part 1a
Part 1 Overview DM199 Preeclampsia Phase 2 IST Trial: Part 1a 〉 27-42 weeks gestation (singleton) Women planned for delivery within 72 hours 〉 >150 systolic blood pressure 〉 Receiving standard of care Part 1A - Dose Escalation (3x3 Design) 〉 <72 hours scheduled for delivery IV → SC dosing sequence (
Slide 18: DM199 Generally Safe and Well Tolerated in Phase 2 IST Trial: Part 1a
DM199 Generally Safe and Well Tolerated in Phase 2 IST Trial: Part 1a 〉No serious TEAEs reported 〉Observed adverse events comparable to those typically seen in this patient population Maternal Treatment-Emergent Adverse Events TEAE N=28 [n(%)] Dose Cohorts Nausea 4 (14%) C8 (n=2), C9 (n=2) Headache
Slide 19: DM199 Was Not Detected in Umbilical Cord Blood after Maternal Dosing
DM199 Was Not Detected (ND) in Umbilical Cord Blood after Maternal Dosing Average Plasma DM199 Concentrations (Maternal and Cord Blood Samples At Delivery) 〉DM199 not detected in any cord blood DM199 Concentration (ng/mL) ND ND ND ND ND ND ND ND ND ND samples 1 C1 & C2 C3 C4 C5 C6 C7 C8 C9 〉Dose-dep
Slide 20: Reduced Blood Pressure at Prespecified 5-Minute Post-Infusion Endpoint
DM199 Reduced Blood Pressure at Prespecified 5-Minute Post-Infusion Endpoint Pooled Cohorts C6–C9 - significant reductions in SBP (-25 mmHg, p=0.0003) and DBP (-13 mmHg, p=0.0007) Systolic Blood Pressure at 5 Minutes Diastolic Blood Pressure at 5 minutes Cohorts 6 – 9 Cohorts 6 – 9 Average Change (m
Slide 21: Significantly Reduced Systolic & Diastolic Blood Pressure
DM199 Significantly Reduced Systolic & Diastolic Blood Pressure Pooled analysis of Cohorts 6-9 (IV: 1-2 μg/kg and SC: 6-12 μg/kg), n=12 Systolic Blood Pressure Diastolic Blood Pressure Severe hypertension (AJOG) -11 -10 Average1 SBP (mmHg) -13 Average1 DBP (mmHg) -15 -14 -18 -17 -13 -13 -13 -17 -22
Slide 22: Significantly Reduced Uterine Artery Resistance
DM199 Significantly Reduced Uterine Artery Resistance Suggests enhanced blood flow to placenta Placental Perfusion 2 〉 Doppler ultrasound measured uterine artery dilation at baseline and 2 hours post IV infusion Reduced blood flow resistance Cohorts 1&21 〉 13.2% average reduction in blood-flow resis
Slide 23: DM199 Two Phase 2 Early Onset Preeclampsia Trials Planned
DM199 Two Phase 2 Early Onset Preeclampsia Trials Planned Preparing to initiate Phase 2 trial in Canada and U.K. and IST in South Africa Study Groups Endpoints Preeclampsia Participants: 30 early-onset preeclampsia participants Phase 2 Trial (N.A. and U.K.) Primary: Safety, tolerability and PK 5, 10
Slide 24: DM199: The Ideal Drug Profile to Treat Preeclampsia
DM199: The Ideal Drug Profile to Treat Preeclampsia Improving endothelial health to improve placental blood flow and lower blood pressure Improved placental DM199 Nitric Oxide Prostacyclin EDHFs VEGF and maternal health Endothelial Placental High Blood Dysfunction Hypoxia Pressure 〉 Restores endothe
Slide 25: Acute Ischemic Stroke
Phase 2/3 Trial: Currently Enrolling Acute Ischemic Stroke
Slide 26: Acute Ischemic Stroke: High Unmet Need with $10B+ U.S. Opportunity
Acute Ischemic Stroke: High Unmet Need with $10B+ U.S. Opportunity 〉7M+ acute ischemic strokes occur globally each year5 and ~700k within the U.S.1-3 〉Only ~20% patients receive either tPA and/or Mechanical Thrombectomy - 1st line therapies3,4 500K+ patients in U.S. with no treatment option HOURS St
Slide 27: Ischemia Naturally Induces Upregulation of Bradykinin 2 Receptors (BK2R)
Ischemia Naturally Induces Upregulation of Bradykinin 2 Receptors (BK2R) DM199 has potential to enhance BK2R activation & promote focal vasodilation in the ischemic penumbra Brain Artery Under Different Conditions 1 2 3 Normal Conditions Ischemic Conditions Ischemic Conditions + DM199 ENDOTHELIAL CE
Slide 28: DM199: May Improve Collateral Circulation in Acute Ischemic Stroke
DM199: May Improve Collateral Circulation in Acute Ischemic Stroke Novel mechanism with potential to improve stroke outcomes & reduce risk of stroke recurrence Early stroke No DM199 treatment DM199 treatment DM199 does not need to pass the blood-brain barrier to deliver therapeutic benefit. DM199 fa
Slide 29: Human Urinary-Derived KLK1 (HUK): Safe and Efficacious Treatment for AIS
Human Urinary-Derived KLK1 (HUK): Safe and Efficacious Treatment for AIS Guided DM199 development, informing optimal dosing, target patients, & treatment protocols 〉HUK for AIS: – Marketed by Shanghai Pharmaceuticals under Kailikang® – Ameliorates neurological symptoms with few adverse events1 〉Up t
Slide 30: Urinary Human KLK1 Improved Cerebral Blood Flow and Stroke Outcomes
Urinary Human KLK1 (uhKLK1) Improved Cerebral Blood Flow and Stroke Outcomes MTT (Mean Transit Time) assesses blood flow velocity in the brain of AIS patients Control uhKLK1 % Change in MTT Proportion of mRS ≤2 (Day 12 vs. Baseline) (At 90 Days) Treatment 19.4% 72.4% Before % Δ at Day 12 vs. Baselin
Slide 31: AIS Phase 2 Results: Improved Excellent Outcomes in Non-MT Subgroup
DM199 AIS Phase 2 Results: Improved Excellent Outcomes in Non-MT Subgroup Patient population closely aligns with ReMEDy2 Phase 2/3 trial mRS ≤ 1 at 90 Days (Non-MT Participants) +19% +15% NIHSS 6-25 Baseline NIHSS 6-15 Baseline Relative Increase 150% 146% Absolute Increase 15% 19% MT – Mechanical Th
Slide 32: AIS Phase 2 Results: Comparison with tPA Data
DM199 AIS Phase 2 Results: Comparison with tPA Data Clinically relevant outcomes with DM199 offering treatment window to 24 hours Comparison of Absolute Improvements in mRS ≤ 1 vs Placebo (DM199 Phase 2 and tPA analysis; excludes MT treated participants) % of Participants at Day 90 vs Placebo 18%* 〉
Slide 33: DM199 AIS Phase 2/3 Pivotal Trial
DM199 AIS Phase 2/3 Pivotal Trial Overview Endpoints at Day 90 〉 Moderate AIS: NIHSS: 5-15 DM199 (rhKLK1) Primary: 〉 Adaptive Design Modified Rankin Score (mRS) ≤1 R 1:1 randomization – Interim analysis @ N=200 Secondary: – Intended to enroll N=~300 Placebo mRS shift, mortality, NIHSS, BI and 〉 Up t
Slide 34: Corporate Summary
Corporate Summary "Z DiaMedica AWS Wy
Slide 35: DM199 Multi-layered IP and Exclusivity Position
DM199 Multi-layered IP and Exclusivity Position Key manufacturing challenges solved: protein activity, stability and economical scale Protein Development Patents and Exclusively Regulatory & Trade Secrets Licensed Technology Exclusivity DM199 (rhKLK1): Excellent Enzymatic Patents1 U.S.: Anticipate 1
Slide 36: Leadership Board of Directors
Leadership Board of Directors Rick Pauls, President & Chief Executive Officer James Parsons, Chairman of the Board CEO of DiaMedica since 2010. Former venture capitalist with two 20+ years as a life sciences CFO for several companies. Former CFO Trillium Therapeutics funds, including co-founder and
Slide 37: Company Overview
Lead Program: DM199 - Novel, Late-Stage Biologic Therapy 〉 Recombinant KLK1 (rhKLK1) protein with FDA Fast-Track Designation 〉 IP until '39 (+ potential 5-year ext.) & expected 12 years regulatory exclusivity 〉 >300 patients dosed with DM199 across multiple studies Preeclampsia (PE) and Fetal Growth
Slide 38: Thank You!
Thank You! Nasdaq: dmac www.diamedica.com
Slide 39: Phase 2 CKD Trial Demonstrated Sustained Systolic Blood Pressure Reduction
DM199 Phase 2 CKD Trial Demonstrated Sustained Systolic Blood Pressure Reduction Systolic Blood Pressure (SBP) was Only Reduced in Cohorts with Baseline SBP >130 mmHg 〉 Baseline >140 mmHg (-13 mmHg, p=0.004) and >150 mmHg (-22 mmHg, p=0.003) 〉 Participants received SC dosing and were on optimized bl
DiaMedica Therapeutics — Investor Presentation (June 2026) on 6ix